ArticleMolecular metabolism2019
Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice.
Article in Molecular metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.American journal of physiology. Endocrinology and metabolism · 2022Trial
- FAP deficiency attenuates T2DM-associated HFpEF by suppressing the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway.Clinical science (London, England : 1979) · 2025Article
- Boron-containing compounds as labels, drugs, and theranostic agents for diabetes and its complications.World journal of diabetes · 2024Article
- FAP expression in adipose tissue macrophages promotes obesity and metabolic inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents.Molecules (Basel, Switzerland) · 2023Review
- FGF21-FGFR1 controls mitochondrial homeostasis in cardiomyocytes by modulating the degradation of OPA1.Cell death & disease · 2023Article
- Boron-Containing Compounds for Prevention, Diagnosis, and Treatment of Human Metabolic Disorders.Biological trace element research · 2023Review
- Plasma proteomic changes in response to exercise training are associated with cardiorespiratory fitness adaptations.JCI insight · 2023Article
- Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein.ChemMedChem · 2021Article
- The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.Nature reviews. Endocrinology · 2020Review
- The role of fibroblast activation protein in progression and development of osteosarcoma cells.Clinical and experimental medicine · 2020Article
- Fibroblast activation protein restrains adipogenic differentiation and regulates matrix-mediated mTOR signaling.Matrix biology : journal of the International Society for Matrix Biology · 2019Article
- The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice.Molecular metabolism · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveFibroblast Activation Protein (FAP), an enzyme structurally related to dipeptidyl peptidase-4 (DPP-4), has garnered interest as a potential metabolic drug target due to its ability to cleave and inactivate FGF-21 as well as other peptide substrates. Here we investigated the metabolic importance of FAP for control of body weight and glucose homeostasis in regular chow-fed and high fat diet-fed mice.
methodsFAP enzyme activity was transiently attenuated using a highly-specific inhibitor CPD60 and permanently ablated by genetic inactivation of the mouse Fap gene. We also assessed the FAP-dependence of CPD60 and talabostat (Val-boroPro), a chemical inhibitor reportedly targeting both FAP and dipeptidyl peptidase-4
resultsCPD60 robustly inhibited plasma FAP activity with no effect on DPP-4 activity. Fap gene disruption was confirmed by assessment of genomic DNA, and loss of FAP enzyme activity in plasma and tissues. CPD60 did not improve lipid tolerance but modestly improved acute oral and intraperitoneal glucose tolerance in a FAP-dependent manner. Genetic inactivation of Fap did not improve glucose or lipid tolerance nor confer resistance to weight gain in male or female Fap
conclusionAlthough pharmacological FAP inhibition improves glucose tolerance, the absence of a metabolic phenotype in Fap
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.